Galderma Premieres Positive Interim Results Demonstrating the Efficacy of Its Injectable Aesthetics Portfolio in Addressing Facial Volume Loss as a Result of Medication-driven Weight Loss
Galderma (SWX:GALD) announces positive first results from a trial designed to explore the benefits of Restylane® Lyft™ or Contour™ in combination with Sculptra® in patients with medication-driven weight loss with associated facial volume loss.1 Initial three-month interim data from this first-of-its-kind trial suggest that this treatment combination effectively improved facial aesthetic appearance with high patient satisfaction.1 The results will be presented later today at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California.
Rates of medication-driven weight loss have increased rapidly in recent years and can be associated with facial alterations of variable magnitude.2-4 Patients can find that their skin is less radiant, drier or saggy, and can also observe changes in their facial structure and balance.3,4 Some even find that they appear older than their age.3,4 There are several reasons for these facial alterations including loss of fat, collagen, elastin and essential nutrients such as fatty acids.4
“We initiated this trial because we have the unique expertise, capability, and products needed to rapidly respond to the evolving needs of patients and healthcare professionals. It is encouraging to see these early results, which demonstrate the potential of our existing Injectable Aesthetics portfolio in addressing the effects of medication-driven weight loss on the skin, and we’re looking forward to presenting the nine-month data in due course.” FLEMMING ØRNSKOV, M.D., MPH
|
Three-month interim data provide response to one of the most predominant aesthetic concerns of patients taking prescription weight loss medicines
In a phase IV clinical trial conducted in the U.S., Galderma investigated the efficacy, safety, and patient satisfaction of Restylane Lyft™ or Contour™ in combination with Sculptra for cheek augmentation and correction of contour deficiencies in patients with medication-driven weight loss with associated facial volume loss.1 Informed by insights gained from pivotal trials of Sculptra and the Restylane portfolio, the trial took place across two sites and used the SHAPE Up Holistic Individualized Treatment (HIT™) as a treatment methodology.1 HIT™ is an individualized treatment approach which enables injectors to leverage their expertise with the renowned Galderma Restylane portfolio to optimize aesthetic outcomes while prioritizing patient satisfaction.
Patients were treated with Sculptra and either Restylane Lyft™ or Contour™ for their first treatment, a second treatment of Sculptra with an optional touch-up of Restylane Lyft™ or Contour™ at Week 4, and an optional third treatment of Sculptra at Week 8.1 Follow-up visits took place at Week 20 for those who received the third Sculptra treatment and at Week 16 for those who did not, corresponding to three months after their final treatment.1
Results at three months demonstrated that the combination of Sculptra and Restylane Lyft™ or Contour™ effectively improved the facial aesthetic appearance of patients experiencing significant medication-driven weight loss with associated facial volume loss, further supporting the benefits of the SHAPE Up HIT™:1
- Three months after their final treatment, subjects showed improved mid-face shape and contouring along with improvements in cheek wrinkles and an overall improvement in facial appearance1
-
Skin quality findings, which were assessed and reported in the Sculptra/Restylane Lyft™ regimen, demonstrated improvements beyond visual improvement; with Sculptra significantly improving skin radiance and skin thickness three months after final injection treatment1
- Additionally, results showed Restylane Lyft™ significantly improved skin hydration as early as Week 4, which was maintained at the three-month follow-up visit1
-
Subjects reported high satisfaction as early as four weeks after their first treatment session, which was maintained through to three months after their treatment1
- At Week 4, 85% said their face looked more refreshed, and almost 80% noticed their facial balance was improved, and said the SHAPE Up HIT™ enhanced their face’s structural harmony1
- 89% felt more attractive and happier with their appearance and agreed it provided natural looking results at three months post follow-up1
Safety was in line with previous pivotal trial data for all products, with no treatment-related adverse events reports.1
“As medication-driven weight loss becomes more prolific around the world, so do the associated impacts of facial volume loss and other unwanted cosmetic effects like shadowing and hollowness. This innovative study is going to be invaluable in exploring how best to address these facial alterations, with results so far being very promising.” MICHAEL SOMENEK, MD
|
Galderma’s broad portfolio addresses key patient and healthcare professional needs
Galderma is well-positioned to address these alterations, given its expertise and experience in dermatology, specialized range of injectable treatments and skincare products, and its patient-centric approach, developed in close collaboration with leading healthcare professionals. While Sculptra - the first proven regenerative biostimulator with a unique poly-L-lactic acid (PLLA-SCA™) formulation - can help to restore skin integrity, our portfolio of Restylane hyaluronic acid injectables can help refine areas of the face that may have been altered during the weight loss journey.1,5-9
A six-month extension is now ongoing to confirm the long-term effects, a full nine months after final Sculptra treatment, to further confirm the benefits of the combination approach.
About the study
This phase IV trial was a multi-center, open-label study to evaluate the synergistic effects of Restylane® Lyft™ or Contour™ in combination with Sculptra® for cheek augmentation and correction of contour deficiencies, in patients experiencing facial volume loss following treatment with one of four brands of glucagon-like peptide-1 (GLP-1) receptor agonists.1 Conducted in the U.S., the trial took place across two sites, and used the SHAPE Up Holistic Individualized Treatment (HIT™) as a treatment methodology, with patients treated with Sculptra and either Restylane Lyft™ or Contour™ for their first treatment, a second treatment of Sculptra with an optional touch-up of Restylane Lyft™ or Contour™ at Week 4, and an optional third treatment of Sculptra at Week 8.1 Follow-up visits took place at Week 20 for those who received the third Sculptra treatment and at Week 16 for those who did not.1 Skin quality findings were assessed in the Sculptra/Restylane Lyft™ regimen.1
About Galderma
Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.
References
- Galderma. Data on file. Somenek M and Lorenc P. A multi-center, open-label study to evaluate the synergistic effects of biostimulator and dermal fillers for cheek augmentation and correction of contour deficiencies.
- Mansour MR, et al. The rise of “Ozempic Face”: Analyzing trends and treatment challenges associated with rapid facial weight loss induced by GLP-1 agonists. JPRAS. 2024;96:225-227. doi: 10.1016/j.bjps.2024.07.051
- Tay JQ. Ozempic face: A new challenge for facial plastic surgeons. JPRAS. 2023;81:97-98. doi: 10.1016/j.bjps.2023.04.057
- Humphrey CD and Lawrence AC. Implications of Ozempic and other GLP-1 receptor agonists for facial plastic surgeons. Facial Plast Surg. 2023;39:719-721
- Sculptra®. EU Instructions for Use. 2021. Available online. Accessed January 2025
- Widgerow A, et al. A randomized, comparative study describing the gene signatures of Poly-L-Lactic Acid (PLLA-SCA) and Calcium Hydroxylapaptite (CaHA) in the treatment of nasolabial folds. Poster presented at IMCAS World Congress, February 1-3, 2024, Paris, France
- Galderma. Data on File (MA-60875)
- Zhang Y, et al. In vivo inducing collagen regeneration of biodegradable polymer microspheres. Regen Biomater. 2021;8(5):rbab042. doi: 10.1093/rb/rbab042
- Huth S, et al. Molecular Insights into the effects of PLLA_SCA on Gene Expression. J Drugs Dermatol. 2024;23(4):285-288. doi: 10.36849/JDD.779
View source version on businesswire.com: https://www.businesswire.com/news/home/20250113255472/en/
Contacts
For further information:
Christian Marcoux, M.Sc.
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50
Sébastien Cros
Corporate Communications Director
sebastien.cros@galderma.com
+41 79 529 59 85
Emil Ivanov
Head of Strategy, Investor Relations, and ESG
emil.ivanov@galderma.com
+41 21 642 78 12
Jessica Cohen
Investor Relations and Strategy Director
jessica.cohen@galderma.com
+41 21 642 76 43
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Thales Introduces New FIDO Key Lifecycle Management Solution to Enable Secure Authentication at Scale12.2.2025 10:00:00 EET | Press release
Thales, the leading global technology and security provider, today announced the launch of OneWelcome FIDO Key Lifecycle Management, a new solution to help large organizations successfully deploy and manage FIDO security passkeys at scale. This announcement reflects Thales’s commitment to provide its customers with a seamless and secure passwordless journey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250212408374/en/ ©Thales OneWelcome FIDO Key Lifecycle Management combines an interoperable management platform with Thales hardware FIDO security keys (passkeys) specifically designed by Thales for use in large organizations. The solution helps CISOs accelerate and secure their passwordless journey by managing FIDO security keys at scale, in a simple and efficient way, throughout their lifecycle. In addition, CISOs benefit from the ultimate Thales expertise in cyber security and in complex projects. Danny de Vreeze, Vice Pr
JT Group Recognized on CDP’s “Climate Change A List” For the 6th Consecutive Year12.2.2025 08:30:00 EET | Press release
Japan Tobacco Inc. (JT) (TSE: 2914) has been recognized for its leadership in corporate sustainability by the global environmental non-profit organization CDP, for the sixth year in a row. The JT Group is one of the companies to be included on the Climate Change A List, out of more than 24,800 companies participating in the 2024 CDP environmental disclosure program. The JT Group achieved a place on CDP's prestigious "A List" for tackling climate change for the sixth consecutive year. We believe that as nature, society, and people’s lives are intertwined, sustaining our ways of living, and the activities of corporate entities, will depend on the sustainability of the environment and societies in which we live. In pursuing the 4S model, JT Group’s management principle, and by realizing the JT Group Purpose, the Company ensures to contribute to the sustainability of the environment and society, through its commitment to working on the material issues identified. As a part of the ecosystem
Inaugural Dealroom and NATO Innovation Fund Report Reveals Record-Breaking Investing in Startups in European Defence, Security, and Resilience Sector12.2.2025 07:05:00 EET | Press release
Dealroom.co and the NATO Innovation Fund - a €1 billion VC (Venture Capital) backed by 24 NATO countries – published today their inaugural report on the state of Defence, Security and Resilience in Europe, revealing a record-breaking year for investing in this segment. This highlights the critical role that the sector is playing in maintaining Europe’s technological edge and sovereignty amidst a broader market downturn. Key findings from the report reveal: VC funding in the DSR (defence, security and resilience) sector is at an all-time high, reaching $5.2 billion in 2024. Overall, investing is up nearly 5x in the last six years. With companies in early and breakout stages driving this growth, a strong pipeline to scaling is expected in the coming years. DSR investing has increased by 30 percent over the past two years - the strongest growth among all VC deep tech segments. The segment has significantly outperformed the overall VC market, which witnessed a 45 percent decline in the sam
Klook Closes $100 Million Investment to Fuel Next Decade of Travel Experiences Growth12.2.2025 04:00:00 EET | Press release
Klook, a leading platform for experiences and travel services in Asia, today announced US$100 million in funding led by the global growth investment firm Vitruvian Partners. The latest investment underscores continued confidence in Klook’s vision, market leadership, and operational excellence as the company accelerates its efforts to capture the fast-growing market of next generation travelers and deepen its reach across Asia Pacific. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250211163358/en/ Founded in 2014, Klook inspires and enables more moments of joy for travelers with curated quality experiences ranging from the biggest attractions to paragliding adventures, iconic museums to rich cultural tours, and other convenient local travel services across 2,700 destinations around the world. (Photo: Business Wire) Marking its 10th anniversary in 2024, Klook has been instrumental in redefining how travelers discover and book
Esri Developer & Technology Summit Features Expanded Program to Reflect Growth of Geospatial Development12.2.2025 00:41:00 EET | Press release
On March 11, 2025, Esri, the global leader in geographic information system (GIS) technology, is hosting the Developer & Technology Summit in Palm Springs, California. Over the past 20 years, the event—formerly known as the Esri Developer Summit—has evolved significantly to support Esri’s growing user community of developers, system architects and admins, DevOps and security engineers, and builders. This year’s attendees can look forward to an expanded range of technical content covering the latest developer tools and IT implementations. Those attending this year’s conference will learn how to: Leverage the latest Esri SDKs, open-source libraries, and data services to build cutting-edge spatial solutions. Architect and manage enterprise GIS systems to be scalable, performant, and secure. Configure custom solutions and extend and automate systems using ArcGIS Maps SDKs, scripting, APIs, and ArcGIS Location Services. Integrate ArcGIS with other technologies, such as AI, across the enterp
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom